Published in Alcohol on June 01, 2007
Signalling pathways in alcohol-induced liver inflammation. J Hepatol (2009) 2.29
Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury. Gastroenterology (2008) 1.90
Molecular mechanisms of alcoholic fatty liver. Alcohol Clin Exp Res (2008) 1.59
Molecular mechanisms of alcoholic liver disease: innate immunity and cytokines. Alcohol Clin Exp Res (2011) 1.35
Pathogenesis of alcoholic liver disease: the role of nuclear receptors. Exp Biol Med (Maywood) (2010) 1.00
Autologous bone marrow mononuclear cell transplantation in patients with decompensated alcoholic liver disease: a randomized controlled trial. PLoS One (2013) 0.99
Liver regeneration. Hepatology (2006) 7.52
Global challenges in liver disease. Hepatology (2006) 4.55
Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology (2004) 3.84
Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells. Hepatology (2004) 3.09
Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci U S A (2001) 3.06
Stat3 protects against Fas-induced liver injury by redox-dependent and -independent mechanisms. J Clin Invest (2003) 3.02
Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev (2006) 2.73
Alcohol and oxidative liver injury. Hepatology (2006) 2.50
Oxidants and antioxidants in alcohol-induced liver disease. Gastroenterology (2003) 2.37
STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration. J Biol Chem (2002) 2.28
Current concepts in the pathogenesis of alcoholic liver injury. FASEB J (2001) 2.08
Cytokines, STATs and liver disease. Cell Mol Immunol (2005) 2.04
Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology (2005) 2.02
In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. Gastroenterology (2003) 2.00
STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology (2006) 1.80
Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology (2005) 1.78
Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology (2006) 1.68
Hydrodynamic gene delivery of interleukin-22 protects the mouse liver from concanavalin A-, carbon tetrachloride-, and Fas ligand-induced injury via activation of STAT3. Cell Mol Immunol (2004) 1.64
Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. Hepatology (2004) 1.54
Liver regeneration. Adv Biochem Eng Biotechnol (2005) 1.42
Mechanisms of alcohol-induced hepatic fibrosis: a summary of the Ron Thurman Symposium. Hepatology (2006) 1.25
Inhibition of hepatic regeneration in rats by acute and chronic ethanol intoxication. Gastroenterology (1979) 1.24
Ethanol induces redox-sensitive cell-cycle inhibitors and inhibits liver regeneration after partial hepatectomy. Alcohol Clin Exp Res (2002) 1.22
STAT1 contributes to dsRNA inhibition of liver regeneration after partial hepatectomy in mice. Hepatology (2006) 1.19
Ethanol rapidly inhibits IL-6-activated STAT3 and C/EBP mRNA expression in freshly isolated rat hepatocytes. FEBS Lett (1999) 1.03
The effect of chronic ethanol feeding on ornithine decarboxylase activity and liver regeneration. Hepatology (1988) 1.00
Effects of short and long term ethanol on the activation of signal transducer and activator transcription factor 3 in normal and regenerating liver. Biochem Biophys Res Commun (1997) 1.00
Expression of cyclin-dependent kinase inhibitor p21 in human liver. Hepatology (1998) 0.98
Therapeutic potential of interleukin-6 in preventing obesity- and alcohol-associated fatty liver transplant failure. Alcohol (2004) 0.97
Hepatocyte proliferative activity in chronic liver damage as assessed by the monoclonal antibody MIB1 Ki67 in archival material: the role of etiology, disease activity, iron, and lipid peroxidation. Hepatology (1996) 0.97
Hepatocyte proliferation and apoptosis in relation to oxidative damage in alcohol-related liver disease. Alcohol Alcohol (2002) 0.94
Alcoholic liver disease. Curr Opin Gastroenterol (2001) 0.94
Plasma interleukin-6 levels in patients with cirrhosis. Relationship to endotoxemia, tumor necrosis factor-alpha, and hyperdynamic circulation. Scand J Gastroenterol (1996) 0.94
Deficient Stat3 DNA-binding is associated with high Pias3 expression and a positive anti-apoptotic balance in human end-stage alcoholic and hepatitis C cirrhosis. J Hepatol (2005) 0.92
An inhibitor of cyclin-dependent kinase, stress-induced p21Waf-1/Cip-1, mediates hepatocyte mito-inhibition during the evolution of cirrhosis. Hepatology (2005) 0.90
HCV core expression in hepatocytes protects against autoimmune liver injury and promotes liver regeneration in mice. Hepatology (2006) 0.89
Ethanol inhibits the JAK-STAT signaling pathway in freshly isolated rat hepatocytes but not in cultured hepatocytes or HepG2 cells: evidence for a lack of involvement of ethanol metabolism. Clin Biochem (2001) 0.84
Imbalance between cytoproliferation and apoptosis in hepatitis C virus related chronic liver disease. J Viral Hepat (2001) 0.83
Long-term ethanol administration and short- and long-term liver regeneration after partial hepatectomy. J Lab Clin Med (1981) 0.83
Chronic ethanol administration to rats decreases receptor-operated mobilization of intracellular ionic calcium in cultured hepatocytes and inhibits 1,4,5-inositol trisphosphate production: relevance to impaired liver regeneration. J Clin Invest (1996) 0.82
Relationship between hepatocyte proliferative activity and liver functional reserve in human cirrhosis. Hepatology (1996) 0.81
The global burden of liver disease: the major impact of China. Hepatology (2014) 4.23
Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci U S A (2010) 4.17
AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab (2011) 3.98
Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology (2004) 3.84
Liver is the major source of elevated serum lipocalin-2 levels after bacterial infection or partial hepatectomy: a critical role for IL-6/STAT3. Hepatology (2015) 3.10
Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology (2006) 3.03
Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab (2008) 2.91
Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis. Cell Metab (2010) 2.89
Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol (2010) 2.72
Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology (2010) 2.40
Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS. J Clin Invest (2002) 2.40
Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One (2011) 2.17
Mouse model of chronic and binge ethanol feeding (the NIAAA model). Nat Protoc (2013) 2.14
Generation of functional ion-channel tools by E3 targeting. Nat Biotechnol (2005) 2.08
HfOx-based vertical resistive switching random access memory suitable for bit-cost-effective three-dimensional cross-point architecture. ACS Nano (2013) 2.05
Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest (2006) 2.03
In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. Gastroenterology (2003) 2.00
Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J (2007) 1.94
Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury. Gastroenterology (2008) 1.90
Dissociation between liver inflammation and hepatocellular damage induced by carbon tetrachloride in myeloid cell-specific signal transducer and activator of transcription 3 gene knockout mice. Hepatology (2010) 1.82
STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology (2006) 1.80
Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFβ receptor type II mice. Hepatology (2013) 1.78
Loss of signal transducer and activator of transcription 5 leads to hepatosteatosis and impaired liver regeneration. Hepatology (2007) 1.77
Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis. Gastroenterology (2007) 1.75
Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor. J Biol Chem (2003) 1.70
Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target. Int J Biol Sci (2011) 1.70
In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression. Hepatology (2011) 1.69
Hydrodynamic gene delivery of interleukin-22 protects the mouse liver from concanavalin A-, carbon tetrachloride-, and Fas ligand-induced injury via activation of STAT3. Cell Mol Immunol (2004) 1.64
Structure and mechanism of receptor sharing by the IL-10R2 common chain. Structure (2010) 1.63
Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology (2012) 1.61
Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride. Hepatology (2009) 1.61
Molecular mechanisms of alcoholic fatty liver. Alcohol Clin Exp Res (2008) 1.59
Chronic plus binge ethanol feeding synergistically induces neutrophil infiltration and liver injury in mice: a critical role for E-selectin. Hepatology (2013) 1.58
A low energy oxide-based electronic synaptic device for neuromorphic visual systems with tolerance to device variation. Adv Mater (2013) 1.57
Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. Hepatology (2004) 1.54
The complement system in liver diseases. Cell Mol Immunol (2006) 1.54
Activation of natural killer T cells promotes M2 Macrophage polarization in adipose tissue and improves systemic glucose tolerance via interleukin-4 (IL-4)/STAT6 protein signaling axis in obesity. J Biol Chem (2012) 1.53
Inflammation in alcoholic liver disease. Annu Rev Nutr (2012) 1.49
Interferon-alpha activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes. Gastroenterology (2002) 1.48
Effects of methylphenidate on resting-state brain activity in normal adults: an fMRI study. Neurosci Bull (2013) 1.46
IFN-gamma/STAT1 acts as a proinflammatory signal in T cell-mediated hepatitis via induction of multiple chemokines and adhesion molecules: a critical role of IRF-1. Am J Physiol Gastrointest Liver Physiol (2004) 1.42
Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J Leukoc Biol (2007) 1.39
Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. Free Radic Biol Med (2009) 1.38
Molecular mechanisms of alcoholic liver disease: innate immunity and cytokines. Alcohol Clin Exp Res (2011) 1.35
Myeloid STAT3 inhibits T cell-mediated hepatitis by regulating T helper 1 cytokine and interleukin-17 production. Gastroenterology (2009) 1.34
Retinoic acid signaling sensitizes hepatic stellate cells to NK cell killing via upregulation of NK cell activating ligand RAE1. Am J Physiol Gastrointest Liver Physiol (2007) 1.34
Crucial role of IL-4/STAT6 in T cell-mediated hepatitis: up-regulating eotaxins and IL-5 and recruiting leukocytes. J Immunol (2003) 1.34
IL-6 modulates hepatocyte proliferation via induction of HGF/p21cip1: regulation by SOCS3. Biochem Biophys Res Commun (2005) 1.33
Natural killer cells in liver disease. Hepatology (2013) 1.31
Natural killer T cells exacerbate liver injury in a transforming growth factor beta receptor II dominant-negative mouse model of primary biliary cirrhosis. Hepatology (2008) 1.30
IL-6-deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver. Cell Mol Immunol (2004) 1.28
Th17 cells and their associated cytokines in liver diseases. Cell Mol Immunol (2010) 1.25
Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. J Pharmacol Exp Ther (2008) 1.24
Negative regulation of liver regeneration by innate immunity (natural killer cells/interferon-gamma). Gastroenterology (2004) 1.23
Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis. Hepatology (2013) 1.23
Role of STAT3 in liver regeneration: survival, DNA synthesis, inflammatory reaction and liver mass recovery. Lab Invest (2007) 1.22
Ground tit genome reveals avian adaptation to living at high altitudes in the Tibetan plateau. Nat Commun (2013) 1.20
Definition of human autoimmunity--autoantibodies versus autoimmune disease. Autoimmun Rev (2009) 1.20
STAT1 contributes to dsRNA inhibition of liver regeneration after partial hepatectomy in mice. Hepatology (2006) 1.19
CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model. Br J Pharmacol (2010) 1.18
Exposure to chronic high glucose induces beta-cell apoptosis through decreased interaction of glucokinase with mitochondria: downregulation of glucokinase in pancreatic beta-cells. Diabetes (2005) 1.18
Interleukin-22 promotes proliferation of liver stem/progenitor cells in mice and patients with chronic hepatitis B virus infection. Gastroenterology (2012) 1.17
Involvement of natural killer cells in PolyI:C-induced liver injury. J Hepatol (2004) 1.17
Interferon-lambda (IFN-λ) induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytes. J Leukoc Biol (2012) 1.17
Synergistic activation of JNK/SAPK induced by TNF-alpha and IFN-gamma: apoptosis of pancreatic beta-cells via the p53 and ROS pathway. Cell Signal (2005) 1.16
AICAR potentiates ROS production induced by chronic high glucose: roles of AMPK in pancreatic beta-cell apoptosis. Cell Signal (2006) 1.16
Age of Zhoukoudian Homo erectus determined with (26)Al/(10)Be burial dating. Nature (2009) 1.15
Impaired natural killer (NK) cell activity in leptin receptor deficient mice: leptin as a critical regulator in NK cell development and activation. Biochem Biophys Res Commun (2002) 1.15
Transcriptional regulation of cannabinoid receptor-1 expression in the liver by retinoic acid acting via retinoic acid receptor-gamma. J Biol Chem (2010) 1.14
Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment. Hepatology (2014) 1.14
IL-6 prevents T cell-mediated hepatitis via inhibition of NKT cells in CD4+ T cell- and STAT3-dependent manners. J Immunol (2004) 1.14
Progression of chronic liver inflammation and fibrosis driven by activation of c-JUN signaling in Sirt6 mutant mice. J Biol Chem (2012) 1.13
MHC Class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol (2004) 1.13
Poly I:C prevents T cell-mediated hepatitis via an NK-dependent mechanism. J Hepatol (2005) 1.11
Chronic ethanol consumption inhibits hepatic natural killer cell activity and accelerates murine cytomegalovirus-induced hepatitis. Alcohol Clin Exp Res (2006) 1.10
The role of STAT1/IRF-1 on synergistic ROS production and loss of mitochondrial transmembrane potential during hepatic cell death induced by LPS/d-GalN. J Mol Biol (2007) 1.10
Inhibition of alpha interferon (IFN-α)-induced microRNA-122 negatively affects the anti-hepatitis B virus efficiency of IFN-α. J Virol (2012) 1.10
Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis. Hepatology (2014) 1.09
Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver. Proc Natl Acad Sci U S A (2011) 1.09
STAT1 plays an essential role in LPS/D-galactosamine-induced liver apoptosis and injury. Am J Physiol Gastrointest Liver Physiol (2003) 1.08
Inflammation-associated interleukin-6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin-10-deficient mice. Hepatology (2011) 1.07
Aldehyde dehydrogenase 2 deficiency ameliorates alcoholic fatty liver but worsens liver inflammation and fibrosis in mice. Hepatology (2014) 1.06
Effect of biochar amendment on sorption and leaching of nitrate, ammonium, and phosphate in a sandy soil. Chemosphere (2012) 1.06
Simultaneous immobilization of lead and atrazine in contaminated soils using dairy-manure biochar. Environ Sci Technol (2011) 1.05
Structural and functional insights of RANKL-RANK interaction and signaling. J Immunol (2010) 1.05
Suppression of innate immunity (natural killer cell/interferon-γ) in the advanced stages of liver fibrosis in mice. Hepatology (2011) 1.05
Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases. Am J Physiol Gastrointest Liver Physiol (2008) 1.05
Integrated assessment of heavy metal contamination in sediments from a coastal industrial basin, NE China. PLoS One (2012) 1.04
Innate immunity and alcoholic liver fibrosis. J Gastroenterol Hepatol (2008) 1.04
Dairy-manure derived biochar effectively sorbs lead and atrazine. Environ Sci Technol (2009) 1.04
Interleukin-6 is an important mediator for mitochondrial DNA repair after alcoholic liver injury in mice. Hepatology (2010) 1.04
Interferon-gamma inhibits interferon-alpha signalling in hepatic cells: evidence for the involvement of STAT1 induction and hyperexpression of STAT1 in chronic hepatitis C. Biochem J (2004) 1.03
Anti-influenza virus effect of aqueous extracts from dandelion. Virol J (2011) 1.03
Stochastic learning in oxide binary synaptic device for neuromorphic computing. Front Neurosci (2013) 1.03
Cytokines and STATs in Liver Fibrosis. Front Physiol (2012) 1.02
Interleukin-22 ameliorates cerulein-induced pancreatitis in mice by inhibiting the autophagic pathway. Int J Biol Sci (2012) 1.02
Biochar from anaerobically digested sugarcane bagasse. Bioresour Technol (2010) 1.00
Anti-inflammatory and anti-apoptotic roles of endothelial cell STAT3 in alcoholic liver injury. Alcohol Clin Exp Res (2010) 1.00
Liver immunology. Compr Physiol (2013) 0.99